April 22nd 2024
Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA’s ODAC Finds Cilta-Cel Favorable in R/R Multiple Myeloma
March 15th 2024During an Oncologic Drugs Advisory Committee Meeting, the FDA found that ciltacabtagene autoleucel has a favorable benefit/risk profile in relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy and are refractory to lenalidomide.
Read More
Immune Engager Therapies Show Best PFS in RRMM Post CAR T-Cell Therapy
February 23rd 2024A retrospective study of real-world patients showed that immune engager therapies had the best response and progression-free survival rates in patients with multiple myeloma who had a relapse after idecabtagene vicleucel treatment.
Read More
Brexu-cel Shows Feasibility in Treating CNS in B-Cell Acute Lymphoblastic Leukemia
February 22nd 2024A retrospective study demonstrated the feasibility and efficacy of brexucabtagene autoleucel in treating central nervous system involvement in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Read More
Axi-cel Improves OS vs SOC in Older Patients With Large B-Cell Lymphoma
December 10th 2023Results from the phase 3 ZUMA-7 trial showed superior progression-free survival and overall survival in patients 65 and older with large B-cell lymphoma with axicabtagene ciloleucel compared with standard of care.
Read More
Single and Dual-Target D8 CAR T Cells Show Tolerability, Efficacy in R/R MM
December 10th 2023Investigators in the MCARTY study reported safety and high response rates in a small number of patients with relapsed/refractory multiple myeloma who received chimeric antigen receptor T-cell therapy designed with a new process to target the D8 binder, meant to improve efficacy in targeting BCMA.
Read More
Outpatient CAR T-Cell Therapy Process Improved by Virtual Care Platform
December 10th 2023Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.
Read More
Do Race and Ethnicity Affect Response to CAR T-Cell Therapy?
October 27th 2023While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.
Read More
Cilta-Cel Continues to Elicit Positive Responses in R/R Multiple Myeloma
October 24th 2023In an interview with Targeted Oncology, Yi Lin, MD, PhD, discussed the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.
Read More